Immunity induction agent

Abstract

Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.

1 . An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a) to (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide, said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:
 (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING;   (b) a polypeptide having a sequence identity of not less than 85% to said polypeptide (a) and composed of not less than 7 amino acids; and   (c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence thereof.   
     
     
         2 . The immunity-inducing agent according to  claim 1 , wherein said polypeptide having immunity-inducing activity is a polypeptide having the amino acid sequence of SEQ ID NO:4, 2, 22 or 24 in SEQUENCE LISTING. 
     
     
         3 . The immunity-inducing agent according to  claim 1 , which is an agent for treating antigen-presenting cells. 
     
     
         4 . The immunity-inducing agent according to  claim 1 , which is a therapeutic and/or prophylactic agent for a cancer(s). 
     
     
         5 . The immunity-inducing agent according to  claim 4 , wherein said cancer(s) is/are a cancer(s) expressing SCD1. 
     
     
         6 . The immunity-inducing agent according to  claim 4 , wherein said cancer(s) is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma, neuroblastoma, mastocytoma, renal cancer, liver cancer, lung cancer, prostate cancer and/or leukemia. 
     
     
         7 . The immunity-inducing agent according to  claim 1 , further comprising an immunoenhancer. 
     
     
         8 . The immunity-inducing agent according to  claim 7 , wherein said immunoenhancer is at least one selected from the group consisting of Freund's incomplete adjuvant; Montanide; poly-I:C and derivatives thereof; CpG oligonucleotides; interleukin-12; interleukin-18; interferon-α; interferon-β; interferon-ω; interferon-γ; and Flt3 ligand. 
     
     
         9 . The immunity-inducing agent according to  claim 2 , which is an agent for treating antigen-presenting cells. 
     
     
         10 . The immunity-inducing agent according to  claim 2 , which is a therapeutic and/or prophylactic agent for a cancer(s). 
     
     
         11 . The immunity-inducing agent according to  claim 5 , wherein said cancer(s) is/are breast cancer, brain tumor, colon cancer, perianal adenocarcinoma, neuroblastoma, mastocytoma, renal cancer, liver cancer, lung cancer, prostate cancer and/or leukemia. 
     
     
         12 . The immunity-inducing agent according to  claim 2 , further comprising an immunoenhancer. 
     
     
         13 . The immunity-inducing agent according to  claim 3 , further comprising an immunoenhancer. 
     
     
         14 . The immunity-inducing agent according to  claim 4 , further comprising an immunoenhancer. 
     
     
         15 . The immunity-inducing agent according to  claim 5 , further comprising an immunoenhancer. 
     
     
         16 . The immunity-inducing agent according to  claim 6 , further comprising an immunoenhancer.